Abstract
The aim of this study is to evaluate clinical benefits of recombinant adenoviral human p53 (rAd-p53) gene therapy combined with radiotherapy in prevention of oral cancer recurrence after a radical resection. A total of 51 patients with tongue cancer (TCa) and 56 patients with gingival carcinoma (GCa) satisfying the inclusion criteria were randomly assigned to two groups: the experiment group (EG) and the control group (CG). The EG group received multipoint injections of rAd-p53 into the surgical wound surface at a dose of 1 × 1012 viral particles after a radical resection. Patients in both EG and CG were given radiotherapy at a total dose of 60 Gy at 3 weeks after surgery. All these patients were followed up for at least 3 years. Two cases (2/27) of TCa and 2 (2/30) in GCa patients had a local recurrence in EG, but 8 (8/24) TCa and 8 (8/26) GCa patients in CG had a local recurrence. Both recurrent rates of TCa (33.3%) and GCa (30.8%) in CG are statistically significantly higher than those of TCa (7.4%) and GCa (6.7%) in EG, respectively. The overall recurrent rate in EG is 7%, which is also statistically significantly lower than that (32%) in CG. The 3-year overall survival (OS) rate and 3-year disease-free survival (DFS) rate of EG is 100% and 93%, respectively. The 3-year OS and DFS rates of CG are 94 and 68%, respectively. Mild or medium fever and flu-like symptoms were more frequently observed in EG and were considered to be associated with application of rAd-p53. Post-tumorectomy wound surface injection of rAd-p53 combining with radiotherapy is a safe and effective regimen for the patients with TGa or GCa.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sakai. E . The p53 tumor suppressor gene and ras oncogene mutations in oral squamous cell carcinoma. Int J Cancer 1992; 52: 867–872.
Yamazaki Y, Chiba I, Hirai A, Sugiura C, Notani K, Kashiwazaki H et al. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol 2003; 39: 163–169.
Seemann S, Maurici D, Olivier M, de Fromentel CC, Hainaut P . The tumor suppressor gene TP53: implications for cancer management and therapy. Crit Rev Clin Lab Sci 2004; 41: 551–583.
Kirsch DG, Kastan MB . Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16: 3158–3168.
Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 799–804.
Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL . Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 1999; 44: 143–151.
Yu M, Chen W, Zhang J . p53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma. Anticancer Drugs 2010; 21: 882–884.
Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K et al. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma. J Clin Oncol 2008; 26: 4166–4171.
Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136: 625–630.
Tian G, Liu J, Zhou JS, Chen W . Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009; 20: 389–395.
Huang SH, O'Sullivan B . Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal 2013; 18: 233–240.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
Langendijk JA, Slotman BJ, van der Waal I, Doornaert P, Berkof J, Leemans CR . Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 2005; 104: 1408–1417.
Brown JS, Shaw RJ, Bekiroglu F, Rogers SN . Systematic review of the current evidence in the use of postoperative radiotherapy for oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2012; 50: 481–489.
Huang TY, Hsu LP, Wen YH, Huang TT, Chou YF, Lee CF et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol 2010; 46: 49–55.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY et al. Does adjuvant radiation therapy improve outcomes in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int J Radiat Oncol Biol Phys 2008; 71: 371–376.
Snehal GP, Jatin PS . TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005; 55: 242–258.
Kastan MB, Canman CE, Leonard CJ . P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14: 3–15.
Muller PA, Vousden KH, Norman JC . p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209–218.
Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C et al. Biomarkers Predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009; 15: 7719–7725.
Weller M . Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998; 292: 435–445.
Matsubara H, Kimura M, Sugaya M, Koide Y, Gunji Y, Takegana K et al. Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells. Int J Oncol 1999; 14: 1081–1085.
Qi X, Chang Z, Song J, Gao G, Shen Z . Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs 2011; 22: 556–562.
Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA . High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5–13.
Clayman GL, Frank DK, Bruso PA, Goepfert H . Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 5: 1715–1722.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763–771.
Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750–1758.
Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9: 2075–2082.
Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609–622.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Liu, S., Chen, P., Hu, M. et al. Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer. Cancer Gene Ther 20, 375–378 (2013). https://doi.org/10.1038/cgt.2013.30
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2013.30
Keywords
This article is cited by
-
Drugging p53 in cancer: one protein, many targets
Nature Reviews Drug Discovery (2023)
-
Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
International Journal of Oral Science (2021)
-
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma
Pharmaceutical Medicine (2019)
-
Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation
Tumor Biology (2014)